{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T04:42:23Z","timestamp":1769575343813,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s10147-017-1192-0","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T06:27:15Z","timestamp":1505370435000},"page":"92-97","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma"],"prefix":"10.1007","volume":"23","author":[{"given":"Satoshi","family":"Murahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Takahari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeru","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ichimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Ozaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izuma","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisho","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"key":"1192_CR1","unstructured":"GLOBOCAN (2012) Cancer Incident and mortality worldwide: IARC cancer base no. 11 (Internet). http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx"},{"key":"1192_CR2","unstructured":"Center for Cancer Control and Information Services, National Cancer Center Japan (2016) Projected cancer statistics. http:\/\/ganjoho.jp\/en\/public\/statistics\/short_pred.html"},{"key":"1192_CR3","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/bjs.1800740904","volume":"74","author":"X Aretxabala de","year":"1987","unstructured":"de Aretxabala X, Konishi K, Yonemura Y et al (1987) Node dissection in gastric cancer. Br J Surg 74:770\u2013773","journal-title":"Br J Surg"},{"key":"1192_CR4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s10120-011-0008-6","volume":"14","author":"S Nonaka","year":"2011","unstructured":"Nonaka S, Oda I, Nakaya T et al (2011) Clinical impact of a strategy involving endoscopic submucosal dissection for early gastric cancer: determining the optimal pathway. Gastric Cancer 14:56\u201362","journal-title":"Gastric Cancer"},{"key":"1192_CR5","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"M Sakuramoto","year":"2007","unstructured":"Sakuramoto M, Sasako T, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810\u20131820","journal-title":"N Engl J Med"},{"key":"1192_CR6","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S1470-2045(09)70259-1","volume":"10","author":"N Boku","year":"2009","unstructured":"Boku N, Yamamoto S, Fukuda H et al (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10:1063\u20131069","journal-title":"Lancet Oncol"},{"key":"1192_CR7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36\u201346","journal-title":"N Engl J Med"},{"key":"1192_CR8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215\u2013221","journal-title":"Lancet Oncol"},{"key":"1192_CR9","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s10120-011-0009-5","volume":"14","author":"H Narahara","year":"2011","unstructured":"Narahara H, Iishi H, Imamura H et al (2011) Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301\/TOP-002). Gastric Cancer 14:72\u201380","journal-title":"Gastric Cancer"},{"key":"1192_CR10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s10120-005-0351-6","volume":"9","author":"S Hironaka","year":"2006","unstructured":"Hironaka S, Zenda S, Boku N et al (2006) Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 9:14\u201318","journal-title":"Gastric Cancer"},{"key":"1192_CR11","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","volume":"30","author":"JH Kang","year":"2012","unstructured":"Kang JH, Lee SI, Lim DH et al (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30:1513\u20131518","journal-title":"J Clin Oncol"},{"key":"1192_CR12","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka S, Ueda S, Yasui H et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31:4438\u20134444","journal-title":"J Clin Oncol"},{"key":"1192_CR13","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","volume":"29","author":"A Ohtsu","year":"2011","unstructured":"Ohtsu A, Shah MA, Van Cutsem E et al (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968\u20133976","journal-title":"J Clin Oncol"},{"key":"1192_CR14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31\u201339","journal-title":"Lancet"},{"key":"1192_CR15","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224\u20131235","journal-title":"Lancet Oncol"},{"key":"1192_CR16","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s10120-015-0559-z","volume":"19","author":"K Shitara","year":"2016","unstructured":"Shitara K, Muro K, Shimada Y et al (2016) Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer. Gastric Cancer 19:927\u2013938","journal-title":"Gastric Cancer"},{"key":"1192_CR17","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association (2017) Japanese gastric cancer treatment guideline 2014 (ver. 4). Gastric cancer. 2017; 20(1): 1\u221219","DOI":"10.1007\/s10120-016-0622-4"},{"key":"1192_CR18","doi-asserted-by":"crossref","unstructured":"Wakatsuki T, Zhang W, Yang D et al. (2012) Ethnic gene profile of genes involved in angiogenesis to predict regional bevacizumab efficacy difference in gastric cancer. J Clin Oncol. 30; 15s: suppl abstr. 4026","DOI":"10.1200\/jco.2012.30.15_suppl.4026"},{"key":"1192_CR19","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1200\/JCO.2011.39.9824","volume":"30","author":"E Cutsem Van","year":"2012","unstructured":"Van Cutsem E, de Haas S, Kang YK et al (2012) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 30:2119\u20132127","journal-title":"J Clin Oncol"},{"key":"1192_CR20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26:141\u2013148","journal-title":"Ann Oncol"},{"key":"1192_CR21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1634\/theoncologist.2014-0440","volume":"20","author":"S Ueda","year":"2015","unstructured":"Ueda S, Satoh T, Gotoh M et al (2015) A phase Ib study of safety and pharmacokinetics of ramucirumab in combination with paclitaxel in patients with advanced gastric adenocarcinomas. Oncologist 20:493\u2013494","journal-title":"Oncologist"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-017-1192-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1192-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1192-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T16:43:27Z","timestamp":1602953007000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-017-1192-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["1192"],"URL":"https:\/\/doi.org\/10.1007\/s10147-017-1192-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]}}}